SCHEMBL4677210

SCHEMBL4677210

NCc1ccc(-c2ccccc2-c2cnnn2C(c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.39
P2RX7 Q99572 1/20 0.35
SGK1 O00141 1/20 0.35
KIF11 P52732 1/20 0.34
AKT2 P31751 1/20 0.34
AGTR1 P30556 1/20 0.33
AGTR2 P50052 1/20 0.33
CYP2A6 P11509 1/20 0.33
CSNK2A1 P68400 2/20 0.33
ADRB2 P07550 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
AKT1 P31749 1/20 0.32
TSHR P16473 1/20 0.32
DPP4 P27487 1/20 0.31
TLR8 Q9NR97 1/20 0.31
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9090820 0.83 NPC1 (0.37) AGTR1AGTR2NPC1TP53HPGD
SCHEMBL4246354 0.78 AGTR1 (0.50) TAAR1P2RX7SGK1KIF11AKT2
SCHEMBL3883657 0.72 AGTR1 (0.47) TAAR1SGK1KIF11AGTR1CSNK2A1
SCHEMBL5362598 0.70 TAAR1 (0.77) TAAR1SGK1CYP2A6CSNK2A1ADRB2
SCHEMBL28089504 0.70 TAAR1 (0.68) TAAR1AKT2CYP2A6CSNK2A1ADRB2
Hydrogen Sulfide SCHEMBL27541593 0.68 TAAR1 (0.74) TAAR1SGK1CYP2A6CSNK2A1ADRB2
SCHEMBL27631745 0.68 AGTR1 (0.44) TAAR1P2RX7SGK1KIF11AKT2
SCHEMBL20497362 0.67 CDC7 (0.56) TAAR1P2RX7LOXL2TSHRKDM4E
SCHEMBL27495768 0.67 LOXL2 (0.65) TAAR1CSNK2A1ADRB2LOXL2HRH3
SCHEMBL8532809 0.66 AGTR1 (0.49) AGTR1AGTR2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590343-B1 SYNTHESIS OF 2-BUTYL-3-(2' -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIRO-4,4 -NONENE-4-ONE TEVA PHARMA (IL) 2008-07-16 EP disclosed
US-7312340-B2 Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-12-25 US disclosed
US-20060128967-A1 Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one DOLITZKY BEN-ZION 2006-06-15 US disclosed
US-7038060-B2 Synthesis of 2-butyl-3-(2′-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-05-02 US disclosed
US-20040242894-A1 Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one TEVA PHARMACEUTICALS USA, INC. 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242894-A1 Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one AGTR1, AGTR2, TEK TAAR1 133/4885P2RX7 1321/4885SGK1 3542/4885
US-20060128967-A1 Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one AGTR1, TEK, AGTR2 TAAR1 151/4885P2RX7 1416/4885SGK1 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.